Market Overview

Trillium Therapeutics Up 40% On Data From Lead Cancer Candidates, Pfizer Investment

Trillium Therapeutics Up 40% On Data From Lead Cancer Candidates, Pfizer Investment

Shares of clinical stage immuno-oncology company Trillium Therapeutics Inc's (NASDAQ: TRIL) are trading higher on encouraging updated data from its ongoing lead cancer candidates TTI-622 and TTI-621 that was released after hours Tuesday.

What Happened: Preliminary data from the TTI-621 (SIRPa-IgG1 Fc fusion protein) four-part Phase 1 trial in patients with advanced relapsed or refractory hematologic malignancies showed that weekly infusions of up to 1.4 mg/kg are well-tolerated without dose-limiting thrombocytopenia.

Platelet decreases occurred on dosing days and recovered in two to four days. 

The antitumor activity in the 1mg/kg dose includes one partial response and one complete response in six evaluable patients. Two of those patients were bridged to allogeneic transplantation. The enrollment in the 2mg/kg cohort is underway.

Preliminary data from the TTI-622 (SIRPa-IgG4 fusion protein) two-part Phase 1a trial in patients with relapsed or refractory lymphoma or multiple myeloma safety assessment of the 8mg/kg dosing cohort has been successfully completed, Trillium said.

The cohort showed a 33% response rate (six out of 18 patients), with five partial response and one complete response.

Serious dose-limiting toxicity or thrombocytopenia in the 8mg/kg cohort was observed in one of six evaluable patients.

The enrollment in the 12 mg/kg cohort is underway.

"We expect to declare maximum tolerated doses or recommended phase 2 doses for both molecules either towards the end of this year or in the first half of 2021," Jan Skvarka, Trillium's president and CEO, said in a statement. 

Why It's Important: The data from the study is encouraging, and it raises the chances of the company's success.

Trillium also announced Tuesday that Pfizer Inc. (NYSE: PFE) is backing the company with a $25-million investment. 

JMP Securities maintained a Market Outperform rating on the stock Wednesday and raised the price target from $10 to $14.

TRIL Price Action: Trillium Therapeutics shares were trading 40.06% higher to $13.25 on heavy volume at the time of publication Wednesday.

The shares are up 818% year-to-date, with a market cap of $561.74 million and the stock hitting a 52-week high Wednesday.

Latest Ratings for TRIL

Oct 2020Evercore ISI GroupInitiates Coverage OnOutperform
Sep 2020HC Wainwright & Co.UpgradesNeutralBuy
Sep 2020JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for TRIL
View the Latest Analyst Ratings


Related Articles (TRIL)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Health Care Price Target Reiteration Analyst Ratings Movers Trading Ideas Best of Benzinga

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at